Is Compounded Semaglutide FDA-Approved? What "Not FDA-Approved" Actually Means

No. Compounded semaglutide is not FDA-approved, it is not a generic of any brand product, and it is not interchangeable with one. Any provider who blurs this line is misleading you, and you should hold that against them. What "not FDA-approved" actually means, though, is more specific and more useful than the phrase suggests, and it is worth five minutes to understand properly.

What FDA approval actually covers

FDA approval is a product-and-manufacturer event. A company submits an application for a specific drug product: a specific formulation, strength, and presentation, made in specific facilities, with specified labeling, supported by clinical trial data. When the FDA approves it, the approval covers exactly that product from exactly that manufacturer.

Approval is how brand medications like Ozempic and Wegovy came to market: their manufacturer ran trials, submitted the data, and passed FDA review of the product and its manufacturing.

What compounding is, and why it exists without approval

Pharmacy compounding is the preparation of a medication for an individual patient under a prescriber's order, and it has been part of medical practice far longer than the modern approval system. US law recognizes it explicitly: section 503A of the Food, Drug, and Cosmetic Act sets the conditions under which a state-licensed pharmacy may compound a preparation for a specific patient without that preparation going through FDA approval, which, by definition, a one-patient preparation never could.

The oversight model is different, not absent: 503A pharmacies answer primarily to their state boards of pharmacy, follow USP standards for compounding, and remain subject to FDA authority. Our explainer on 503A versus 503B pharmacies covers this framework in detail.

The honest trade is this: approval reviews the product before market; compounding oversight rests on the pharmacy that prepares it. With a compounded preparation, the pharmacy's licenses and practices carry the weight the FDA review would otherwise carry.

What the FDA has actually said about compounded GLP-1s

The FDA's public position, stated across several alerts and announcements, comes down to these points:

• Compounded GLP-1 medications, including compounded semaglutide, are not FDA-approved, and the agency has expressed concerns about unapproved GLP-1 products marketed for weight loss.
• The agency has documented dosing errors associated with compounded injectable semaglutide, where patients or providers drew up the wrong amount from multi-dose vials.
• With the semaglutide shortage declared resolved in early 2025, the flexibility that allowed large-scale compounding of shortage drugs ended, and the FDA stated its intent to act against non-FDA-approved GLP-1 products in certain contexts.

We link the FDA's own pages in the sources below rather than paraphrasing selectively; they are short and worth reading firsthand.

"Is the FDA banning compounded semaglutide?"

This is the question behind much of the anxiety, so here is the state of play as plainly as we can put it. The FDA has not banned pharmacy compounding; it is established in federal law. What changed after the shortage resolution is the boundary: outside a shortage, a pharmacy may not regularly compound what is essentially a copy of an available FDA-approved product, while compounding tailored to an individual patient's documented clinical needs, under a valid prescription, remains within 503A practice.

Where exactly that boundary sits in specific cases is actively debated and enforced, and the landscape continues to evolve. We will not pretend otherwise, and we treat this as the single most important regulatory question in this category. Two practical consequences for you as a patient: prefer providers who acknowledge this openly, and ask any provider how their pharmacy operates within the current rules. Evasion on this question tells you everything.

What "not FDA-approved" does not mean

• It does not mean illegal. Patient-specific compounding under 503A is lawful pharmacy practice. Legality and approval status are separate questions.
• It does not mean banned or recalled. Those are specific FDA actions against specific products; the phrase "not FDA-approved" describes the absence of premarket review, not an enforcement action.
• It is not, by itself, a safety verdict. No review happened, in either direction. The quality of a compounded preparation rests on the pharmacy: its state licenses, its ingredient sourcing, its testing practices, and its labeling. That can be done carefully or carelessly, which is exactly why the next section matters.

The questions that separate careful pharmacies from careless ones

Whoever your provider is, these questions have verifiable answers:

• Which pharmacy prepares the medication, and in which states is it licensed? The pharmacy should be named, on the label and on request; see how to verify a pharmacy and platform.
• Does the pharmacy test its batches for potency and sterility, and will the provider say so in writing?
• Is the prescription individual? A licensed clinician should review your health history and issue a patient-specific prescription; see how to verify the doctor's license.
• Is the "not FDA-approved" status disclosed plainly, or buried? Majesta discloses it on every relevant page, including this one, because we would rather lose a customer than mislead a patient. How the process works end to end is described at how Majesta works.

The bottom line

Compounded semaglutide is not FDA-approved: no shortcut around that sentence exists, and none should. What the phrase means is that no federal premarket review stands behind the preparation, so the pharmacy's own licenses, standards, and testing carry the weight instead, within a legal framework (503A) built for patient-specific medication. The rules around GLP-1 compounding tightened after the shortage ended and continue to evolve. Choose providers who tell you all of this without being asked, and put your questions to a licensed clinician who knows your situation.

Sources: FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"; FDA, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize"; FDA alert on dosing errors associated with compounded injectable semaglutide; FD&C Act section 503A; USP compounding standards; state board of pharmacy guidance.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Compounded medications are not FDA-approved as final products and are not generic versions of or interchangeable with any brand-name medication.